Category - News

Developments

SELLAS reports positive follow-up data from Phase 1/2 acute myeloid leukemia trial

SELLAS Life Sciences (NASDAQ:SLS) reported final follow-up data from its Phase 1/2 study of galinpepimut-S in patients with acute myeloid leukemia (AML) in second complete remission. The data demonstrate a median...

February 26, 2020

Developments

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) reported positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, at lower...

February 26, 2020

Developments

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

Kane Biotech (TSX-V:KNE) launched its silkstem anti-itch shampoo at the Global Pet Expo taking place on February 26-28, 2020 in Orlando, Florida. silkstem is a scientifically formulated anti-itch shampoo for dogs and...

February 26, 2020

Developments

Kane Biotech signs first U.S. distribution agreement with King Wholesale

Kane Biotech (TSXV:KNE) signed an agreement with King Wholesale, a California-based distributor of wholesale pet supplies. Under the accord, King will distribute Kane’s bluestem oral care and silkstem anti-itch shampoo...

February 25, 2020

Markets

WB starts Precision BioSciences at buy; fair value estimate $20

William Blair launched coverage of Precision BioSciences (NASDAQ:DTIL) with an “outperform” rating and fair value estimate of $20. The stock closed at $8.01 on Feb. 24. Precision has pioneered the development of its...

February 25, 2020

Markets

Roth resumes coverage of Altimmune at buy; PT $13

Roth Capital Partners resumed coverage of Altimmune (NASDSQ:ALT) with a “buy” rating and $13 price target. The stock closed at $1.76 on Feb. 21. “Altimmune represents a buying opportunity with its dual GLP-1: glucagon...

February 24, 2020

Developments

FDA approves Baudax Bio’s ANJESO for pain

The FDA approved Baudax Bio’s (NASDAQ:BXRX) ANJESO for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once-daily COX-2 preferential NSAID that is...

February 21, 2020

Markets

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...

February 21, 2020

Developments

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VBL Therapeutics (NASDAQ:VBLT) launched a Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111, an adenovirus that carries a transgene for the Fas...

February 20, 2020

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Category - News

SELLAS reports positive follow-up data from Phase 1/2 acute myeloid leukemia trial

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

Kane Biotech signs first U.S. distribution agreement with King Wholesale

WB starts Precision BioSciences at buy; fair value estimate $20

Roth resumes coverage of Altimmune at buy; PT $13

FDA approves Baudax Bio’s ANJESO for pain

HCW cuts ReWalk Robotics PT to $3.50 from $9

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VistaGen reports positive results from Phase 2a major depressive disorder study

General

More